Person:
Portero Fuentes, Miriam

Profile Picture
First Name
Miriam
Last Name
Portero Fuentes
URI
https://hdl.handle.net/20.500.14352/81577
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Department
Area
Identifiers
UCM identifierORCIDScopus Author IDDialnet ID

Filters

20221
Reset filters

Settings

Subject: 636.09:616-006.04 ×

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Clinical outcome of dogs diagnosed with canine inflammatory mammary cancer treated with metronomic cyclophosphamide, a cyclooxygenase‐2 inhibitor and toceranib phosphate
    (Veterinary and Comparative Oncology, 2022) Alonso Miguel, Daniel; Valdivia Lara, Edgar Guillermo; García San José, Paula; Alonso Díez, Ángela; Clares, Irene; Portero Fuentes, Miriam; Peña Fernández, Laura Luisa; Pérez Alenza, María De Los Dolores
    Canine inflammatory mammary cancer (IMC) is highly malignant, invasive and a therapeutic challenge, because effective medical treatment is still unavailable. This retrospective study compares the efficacy of an oral cyclooxygenase-2 (COX-2) inhibitor combined with toceranib phosphate and oral cyclophosphamide (multi-drug therapy [MT]) with COX-2 inhibitor therapy alone (single-drug therapy [ST]) in dogs diagnosed with secondary IMC. Clinical response, adverse events, overall survival time (OST), disease-free survival (DFS) and time to progression (TTP) were evaluated. Sixteen patients were included, eight received MT and eight receiving ST. Median OST was significantly higher in patients receiving MT (96.0 vs. 37.5 days; p = .046) and in patients with post-surgical rather than non-surgical IMC (86.5 vs. 41.5 days; p = .038). Additionally, median TTP was significantly higher in patients treated with MT (p = .010). In patients with non-surgical IMC, the clinical benefit (CB) was reached in 100% (n = 3) of patients receiving MT and in 33% (n = 1) of those receiving ST; the response duration was significantly longer in MT cases (p = .026). The absence of disease progression at day 30 of treatment was significantly associated with longer OST, DFS and TTP (p = .018, p = .002 and p < .001, respectively). Adverse events occurred more frequently in patients treated with MT compared with ST (p = .026). The MT protocol produced primarily mild to moderate toxicities, which were resolved with supportive care; therefore, the combination of drugs was adequately tolerated by most of the patients. The combination of toceranib, a COX-2 inhibitor and oral cyclophosphamide may be a protocol with potential therapeutic efficacy for dogs with IMC.